Biotech Co.* |
Pharma Co. (Country) |
Type/Product Area |
Terms/Details (Date) |
| | |||
Abiogen |
BTG plc (UK) |
Agreement for Abiogen to license worldwide intellectual property rights to two compounds to treat anxiety and depression, BTG 1640 and BTG 1675A |
Abiogen made an upfront payment of £2M (US$3.22M); BTG also could receive development-based milestone payments and royalties (7/23) |
|
|
|
|
ActivX |
Pfizer Inc. |
Agreement to further characterize the protein activity in a research compound being developed at Pfizer |
ActivX will use its technology to analyze specific protein activities to provide a greater understanding of the biological activity of Pfizer's compound (7/10) |
|
|
||
Agilent Technologies |
Genomics Institute of the Novartis Research Foundation |
Worldwide licensing agreement that allows Agilent to exclusively commercialize a technology for proteomics applications used in drug research |
The technology is a chemical reagent for the derivatization and mass tagging of protein samples prior to analysis by mass spectrometry (6/2) |
|
|
||
Amrad |
Merck & Co. Inc. |
Exclusive licensing and multiyear research collaboration in which Merck could end up paying up to $112M if it develops products for all indications included in the agreement, such as asthma, other types of respiratory disease and oncology |
Amrad also would receive royalties for commercialized products; Merck will be be responsible for all clinical development and marketing (6/23) |
|
|
||
Applied Molecular Evolution Inc. (AMEV) |
Eli Lilly and Co. |
Agreement to optimize two protein therapeutic candidates for Lilly |
The goal is to apply Applied Molecular's AMEsystem to create optimized versions of both a growth factor and an antibody candidate for clinical development; Applied Molecular will receive an up-front fee and potential milestone payments and royalties (6/24) |
|
|
||
Argenta Discovery |
Teijin Ltd. (Japan) |
Collaboration in which Argenta will exploit a range of approaches to deliver an optimized lead series against a cardiovascular disease target |
Financial terms were not disclosed (6/11) |
|
|
||
Bioenvision Inc. (OTC BB:BIOV) |
Ferro Pfanstiehl Laboratories Inc. |
Agreement for the development and supply of clofarabine to treat acute leukemias |
Ferro gains worldwide development and supply rights, excluding the U.S. and Canada (6/17) |
|
|
||
Biota Holdings Ltd. (Australia; ASX:BTA) |
Sankyo Co. Ltd. (Japan) |
Agreement covering Biota's Flunet and a similar Sankyo compound |
The companies signed a letter of intent to enter an agreement to pool their long- acting neuraminidase inhibitor flu drug pipelines and jointly seek development and commercialization partnerships; companies would share equally in all future licensing and royalty revenues (5/27) |
|
|
||
BioVex Ltd.* (UK) |
Merck & Co. Inc. |
Agreement for BioVex to supply its NeuroVEX vectors to Merck |
Merck will evaluate the vectors designed to allow nontoxic gene delivery to the cells and tissues of the nervous system (6/16) |
|
|
||
Caprion Pharmaceuticals Inc.* (Canada) |
Wyeth |
Collaboration for Caprion to use its CellCarta proteomics discovery platform to identify biomarkers of the effects of pharmaceutical compounds belonging to Wyeth |
Caprion will profile plasma changes in a preclinical model of inflammation after administration of Wyeth's compounds (7/16) |
|
|
|
|
Cardion AG* (Germany) |
Hoffmann-La Roche Inc. |
Agreement giving Roche rights to a preclinical research program with transplant rejection and rheumatoid arthritis applications |
Roche acquired CRB-15; it made an upfront payment and could make milestone payments totaling up to $90M; Cardion also is eligible for royalties (7/22) |
|
|
|
|
Cell Genesys |
Novartis AG (Switzerland) |
Agreement to develop oncolytic virus products |
Cell Genesys will receive exclusive worldwide rights to the oncolytic virus therapy products and related intellectual property of Novartis affiliate Genetic Therapy Inc. along with a payment of $28.5M from Novartis to be dedicated to further development of several oncolytic virus therapy products from both Cell Genesys and GTI (7/23)
|
|
|
|
|
Cel-Sci Corp. (AMEX:CVM) |
Undisclosed company |
Partnership to develop two of Cel-Sci's drugs, Multikine and CEL-1000, in three countries, Greece, Serbia and Croatia |
The strategic partner gained the right to receive a 1% royalty on the future net sales of Multikine and CEL-1000; it also acquired $500,000 of Cel-Sci common stock and warrants (6/2) |
|
|||
CeNeS Pharmaceuticals plc (UK;LSE:CEN) |
Undisclosed company |
Agreement in which CeNeS sold three of its pharmaceutical products |
CeNeS did not disclose the name of the company buying the products for £9M (US$14.7M) in cash, or the names of the products (5/22) |
|
|||
Chiron Corp. (CHIR) |
Baxter AG (subsidiary of Baxter International) |
Licensing agreement for Chiron's HIV and hepatitis C intellectual property in combination with plasma-screening technology belonging to Baxter AG for use with plasma fractionation in Europe |
The licenses will allow Baxter to continue to develop its own large-scale, plasma-testing technology for screening plasma (7/16) |
|
|||
Connetics Corp. (CNCT) |
BAS Medical |
Agreement in which Con- netics sold its rights to recombinant human relaxin to BAS Medical |
Connetics received a $100,000 up-front assignment fee and will receive up to $1M in licensing and milestone fees, as well as royalties on future product sales; BAS assumed rights to develop and commercialize relaxin for all indications (7/21) |
|
|||
Crucell NV (the Netherlands; CRXL) |
Merck & Co. Inc. |
Research license agreement allowing Merck to use the PER.C6 cell line to study the production of certain protein products, including monoclonal antibodies |
Crucell will receive an up-front payment and an annual maintenance fee (6/3) |
|
|||
Debiopharm SA* (Switzerland) |
H3 Pharma Inc. (Canada) |
Agreement giving H3 Pharma the worldwide research, development and commercialization rights to Sanvar to treat acute esophageal variceal bleeding |
Further details were not disclosed (7/2) |
|
|||
Demegen Inc. (OTC BB:DBOT) |
Dow Pharmaceutical Sciences |
Collaborative agreement to develop certain Demegen peptides into pharmaceutical products |
Dow will be responsible for selecting suitable Demegen compounds for several topical disease indications for development and filing FDA applications and for certain other services (6/3) |
|
|||
Discovery Partners International Inc. (DPII) |
Seikagaku Corp. (Japan) |
Agreement in which Discovery Partners' Swiss affiliate entered into an assay development and biological screening collaboration with Seikagaku on an undisclosed target |
Discovery Partners will be working with Seikagaku to adapt an assay to Discovery's screening capabilities as a first step (6/30) |
|
|||
Diversa Corp. (DVSA) |
GlaxoSmithKline plc (UK) |
Agreement in which Diversa acquired a slate of preclinical antifungal compounds and intellectual property from GSK in exchange for equity |
Diversa issued 806,873 shares for the program, valuing the deal at $8.6M; Diversa gets worldwide rights to a group of compounds (7/22) |
|
|||
Entropin Inc. (OTC BB:ETOP) |
Unnamed partner |
Research-based collaboration to develop a topical delivery formulation of ENT-103 |
The partner will combine its excipient, which promotes enhanced absorption of drugs across dermal, mucosal and ocular membranes, with ENT-103 to analyze their compatibility (7/22) |
|
|||
Enzon Pharmaceuticals Inc. (ENZN) |
Fresenius Biotechnology (division of Fresenius AG; Germany) |
Licensing agreement for North American rights to develop and commercialize ATG-Fresenius S, a transplant rejection project |
Enzon will be responsible for the costs related to the North American clinical development and regulatory approval, while Fresenius will manufacture and supply the drug at no charge for the first indication; Fresenius could receive two separate $1M milestone payments (6/17) |
|
|||
Galapagos Genomics NV* (Belgium) |
Procter & Gamble Co. |
Collaboration in the field of osteoporosis |
P&G obtains access to targets discovered by Galapagos and validated in animal models; it will further validate the role of the targets in osteoporosis disease and initiate the development of drugs based on the proteins; Galapagos is eligible for option fees, milestone payments and royalties (6/11) |
|
|
|
|
Gene Logic Inc. (GLGC) |
Solvay Pharmaceuticals (division of Solvay SA; Belgium) |
Agreement in which Solvay subscribed to a CustomSuite product from Gene Logic's BioExpress System |
Solvay will apply the data resource to selected areas of its discovery research efforts (5/28) |
|
|
|
|
Genentech Inc. (NYSE:DNA) |
Novartis AG (Switzerland) |
Agreement giving Novartis rights outside of North America to Genentech's drug Lucentis for the wet form of age-related macular degeneration |
Novartis is buying for an undisclosed sum the development and marketing rights outside the U.S., Canada and Mexico; the companies will share certain development costs; Genentech will receive an up-front fee, payments for clinical development milestones, plus royalties (6/25) |
|
|
|
|
EPIX Medical Inc. (EPIX) |
Schering AG (Germany) |
Agreement to develop contrast agents for use in MRI |
Deal could be worth up to $28M in near- term money for EPIX; it will focus on advancing EP-2104R and developing new compounds to be used in magnetic resonance imaging; Schering gained an option for the late-stage development and worldwide marketing rights to EP-2104R, and for all development candidates that emerge (5/27) |
|
|
|
|
GeneProt Inc.* (Switzerland) |
Novartis Pharma AG (Switzerland) |
Licensing agreement for a Novartis protein |
The protein is one of more than 20 proteins and polypeptides being studied at Novartis and elsewhere (5/23) |
|
|
|
|
Genospectra |
Diagnostics Division of Bayer HealthCare |
Development and distribution agreement to provide Genospectra with access to Bayer Diagnostics' branched DNA technology |
Bayer granted Genospectra exclusive rights to develop and distribute Bayer's QuantiGene branched DNA product line in the life sciences research market (6/11) |
|
|
|
|
Inpharmatica Ltd.* (UK) |
Riken (Japan) |
Agreement in which Riken took a nonexclusive subscription to Inpharmatica's Biopendium |
Biopendium is a proteome annotation resource (7/17) |
|
|
|
|
Kinexis Inc.* |
Merck & Co. Inc. |
Drug discovery program involving biologic target validation and small-molecule screening of a prokineticin receptor in central nervous sytem indications |
Kinexis will receive research funding and may be entitled to future milestone payments and product royalty payments from Merck (7/21) |
|
|
||
Maxygen Inc. (MAXY) |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Agreement focused on Maxygen's interferon alpha and beta variants portfolio |
Roche has rights to candidates for hepatitis B and C, but has options on other indications; the deal could be worth as much as $230M; Maxygen will receive an upfront payment and two years of research and development funding, as well as option fees; it also could receive potential milestone payments (5/22) |
|
|||
Medivir AB (Sweden; SSE:MBIRb) |
Boehringer Ingelheim GmbH (Germany) |
Agreement for develoment of a nuceloside reverse transcriptase inhibitor, MIV-310, for HIV |
The pact is potentially worth €122M (US$136.7M); Medivir retained Nordic marketing rights for the compound, while Boehringer Ingelheim gains rights elsewhere (7/15) |
|
|
|
|
Medivir AB (Sweden; SSE:MVIRb) |
GlaxoSmithKline plc (UK) |
Agreement to develop Medivir's HIV drug MIV-210 |
Deal is worth up to €86M (US$101.1M); Medivir will receive an up-front payment, plus milestones (5/27) |
|
|
|
|
MethylGene Inc.* (Canada) |
Merck-Frosst Canada & Co. (Canada) |
Worldwide license, research, development and commercialization agreement on a small-molecule inhibitor program against bacterial beta-lactamases to fight antibiotic resistance |
MethylGene will provide a synthetic chemisty effort to optimize its small-molecule lead compound into clinical candidates; Merck-Frosst will progress the candidates through clinical development and will be responsible for worldwide commercialization and marketing; MethylGene will receive a US$4M initial fee, with total potential payments up to US$33.75M, as well as royalties (6/25) |
|
|||
Millennium Biologix Inc.* (Canada) |
Procter & Gamble Co. |
Research agreement in which P&G Pharmaceuticals will evaluate the therapeutic potential of Millennium's synthetic BCSP (Bone and Cartilage Stimulating Peptides) growth factors to treat diseases of bone and cartilage |
Millennium has granted P&G an option for the compounds; financial terms were not disclosed (7/8) |
|
|||
Morphotek |
Novo Nordisk A/S (Denmark) |
Agreement for the use of Morphotek's Morphodoma and Direct-Line technology to make improvements to a protein process of a marketed Novo Nordisk therapeutic protein |
Financial terms were not disclosed (7/7) |
|
|||
Neurion Pharmaceuticals Inc.* |
Eli Lilly and Co. |
Alliance to discover small- molecule drugs targeting ion channels for various central nervous system indications |
The collaboration will combine Neurion's Precision Neurochemistry Platform technology with Lilly's discovery resources; Neurion will receive cash payments for its work while Lilly retains an option to negotiate development and marketing rights to compounds identified by Neurion (7/8) |
|
|||
Orphan Medical Inc. (ORPH) |
ESP Pharma Inc. |
Agreement in which Orphan Medical is selling worldwide rights to Busulfex Injection and its current inventory to ESP Pharma |
Further details were not disclosed (6/10) |
|
|||
ParAllele BioScience* |
Merck & Co. Inc. |
Collaboration to conduct a SNP genotyping study using its lab-in-a-tube technology for genetic research |
ParAllele will develop assays, perform multiplexed genotyping and provide data analysis as well as develop certain platform extensions of interest to Merck (7/9) |
|
|
|
|
Peninsula Pharmaceuticals Inc.* |
Shionogi & Co. Ltd. (Japan) |
Agreement in which Peninsula in-licensed an antibiotic, doripenem |
Peninsula has rights to develop the drug and to sublicense it; Shionogi will manufacture the product for worldwide distribution (5/27) |
|
|
||
Pharsight Corp. (OTC BB:PHST) |
Fournier Pharma Inc. (Canada) |
Agreement in which Fournier will engage Pharsight for a modeling and simulation project designed to enhance the drug development process |
Fournier will use Pharsight's modeling and simulation tools for development programs to optimize Fournier's trial design and dosing regimen for specific drug candidates (5/28) |
|
|
||
Philogen S.r.l.* (Italy) |
Schering AG (Germany) |
Exclusive worldwide development and marketing agreement giving Schering access to an antibody-based therapeutic fusion protein |
The compound could have the potential to treat tumors by triggering immunological mechanisms; financial terms were not disclosed (6/26) |
|
|
|
|
Pozen Inc. (POZN) |
GlaxoSmithKline plc (UK) |
Licensing agreement for Pozen's migraine drug MT 400 |
GSK gains exclusive U.S. marketing and commercialization rights to any combination of the drug that uses one of its marketed triptans and the NSAID, for which it would pay sales performance milestones up to $80M, as well as undisclosed royalties; Pozen will receive an up-front fee and initial milestone payment of $25M later this year, with additional milestone payments of potentially $55M (6/13) |
|
|
|
|
Pozen Inc. (POZN) |
Nycomed Group (Denmark) |
Exclusive option agreement under which Pozen may acquire a license to certain rights related to Iornoxicam |
Pozen will evaluate candidates containing lornoxicam alone or in combination with other active ingredients for pain or other indications; Pozen paid an up-front fee of $50,000 and could pay an additional $450,000 depending on certain milestones; Pozen will fund development and retain exclusive commercialization rights in the U.S. and Canada and semi-exclusive rights in certain European countries, while Nycomed will have a right of first negotiation for commercialization rights in Nordic countries (7/22) |
|
|
|
|
Replidyne Inc.* |
GlaxoSmithKline plc (UK) |
Agreement for Replidyne to acquire worldwide rights to an antibacterial program from GSK |
Specific financial terms were not disclosed, though GSK received an equity position in Replidyne (6/17) |
|
|
|
|
Sequenom Inc. (SQNM) |
Bristol-Myers Squibb Co. |
Genetics discovery collaboration in which Sequenom will use its MassArray technology and collection of DNA samples to genetically evaluate specific targets for Bristol-Myers in multiple disease areas |
Bristol-Myers will fund the collaboration and Sequenom could receive milestone payments and royalties (7/10) |
|
|
||
SomaLogic Inc.* |
Beckman Coulter Inc. |
Development agreement in which SomaLogic will undertake a feasibility study aimed at integrating its aptamer protein capture agent technology with Beckman Coulter's Biomek liquid handling workstation and microarray-plate and array reader platforms |
Financial terms were not disclosed (7/23) |
|
|
||
T3 Therapeutics LLC* |
West Pharmaceuticals Services Inc. |
Worldwide agreement for the development and commercialization of an oral sustained-release formulation of liothyronine |
Liothyronine is used to treat congestive heart failure and hypothyroidism (5/29) |
|
|
||
Zealand Pharmaceuticals A/S* (Denmark) |
Aventis SA (France) |
Licensing agreement giving Aventis rights to the Type II diabetes treatment ZP10 |
The deal is worth up to $100M in milestone payments, including a $10M up-front payment, as well as additional royalties; Aventis gains global rights to the product (6/25) |
|
|
||
|
| |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange. | |||
To read more on related topics, click on one of the words below.